Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Antonio PAZZOLA"'
Autor:
Matteo Floris, Daria Sanna, Paolo Castiglia, Carlo Putzu, Valeria Sanna, Antonio Pazzola, Maria Rosaria De Miglio, Francesca Sanges, Giovanna Pira, Antonio Azara, Emanuele Lampis, Antonello Serra, Ciriaco Carru, Maristella Steri, Flavia Costanza, Marco Bisail, Maria Rosaria Muroni
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-15 (2020)
Abstract Background Despite conflicting results, considerable evidence suggests the association between single nucleotide polymorphisms in MTHFR, XRCC1 and OGG1 genes and, risk of developing breast cancer. Here a case-control study is reported, inclu
Externí odkaz:
https://doaj.org/article/431e9ff0f79f4e30811cd02534df8578
Autor:
Elena Verzoni, Giacomo Cartenì, Enrico Cortesi, Diana Giannarelli, Andrea De Giglio, Roberto Sabbatini, Sebastiano Buti, Sabrina Rossetti, Francesco Cognetti, Francesca Rastelli, Alberto Sobrero, Daniele Turci, Cora N. Sternberg, Camillo Porta, Federico Cappuzzo, Giampaolo Tortora, Davide Tassinari, Stefano Panni, Antonio Pazzola, Gianmarco Surico, Alessandra Raimondi, Ugo De Giorgi, Giuseppe Procopio, on behalf of the Italian Nivolumab Renal Cell Cancer Early Access Program group
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-9 (2019)
Abstract Background The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval. Methods Pts with prev
Externí odkaz:
https://doaj.org/article/8dc2e19ba5544857a0d837544b55b59a
Autor:
Benedetta Conte, Chiara Molinelli, Giancarlo Bisagni, Antonio Durando, Giovanni Sanna, Stefania Gori, Ornella Garrone, Stefano Tamberi, Sabino De Placido, Francesco Schettini, Antonio Pazzola, Riccardo Ponzone, Filippo Montemurro, Gianluigi Lunardi, Rosario Notaro, Anna Turletti, Claudia Bighin, Francesca Poggio, Giulia Buzzatti, Matteo Lambertini, Luca Boni, Lucia Del Mastro
Publikováno v:
Cancer Research. 82:P3-09
Background: Extending adjuvant endocrine treatment (ET) with aromatase inhibitors (AI) to 7-10 years decreases the risk of relapse in hormone receptor-positive (HR+) breast cancer (BC). However, such benefit comes at the price of higher incidence of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da49964fa528ee1d0ad346af43eb7161
https://doi.org/10.1158/1538-7445.sabcs21-p3-09-03
https://doi.org/10.1158/1538-7445.sabcs21-p3-09-03
Autor:
Antonio Pazzola, Andrea De Vito, Luigi Angelo Vaira, Giordano Madeddu, Chiara Pes, Giacomo De Riu, Federica Giovanditto, Sergio Babudieri, Giovanna Deiana, Franco Bandiera, Alessandro G. Fois, Jerome R. Lechien, Claire Hopkins, Serge-Daniel Le Bon, Sven Saussez, Vito Fiore, Andrea Piana
Publikováno v:
European Archives of Oto-Rhino-Laryngology
Background Interleukin 6 (IL-6) is a proinflammatory cytokine that is secreted by cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and it is widely recognized as a negative prognostic factor. The purpose of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c09008c71cc05527ce389957cc2fd35
https://doi.org/10.1007/s00405-021-06868-5
https://doi.org/10.1007/s00405-021-06868-5
Autor:
Panagiotis PALIOGIANNIS, Angelo ZINELLU, Arduino A. MANGONI, Antonio PAZZOLA, Francesco L. BANDIERA, Antonio SPANO, Chiara SANNA, Valentina SCANO, Sara S. FOIS, Verdiana MUSCAS, Elena MASOTTO, Stefano DORE, Vito FIORE, Pietro PIRINA, Ciriaco CARRU, Alessandro G. FOIS
Publikováno v:
Minerva Respiratory Medicine. 61
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53d66b6562be80ff73cdf02093b57b71
https://doi.org/10.23736/s2784-8477.21.01982-3
https://doi.org/10.23736/s2784-8477.21.01982-3
Autor:
Valeria Sanna, Palma Fedele, Giulia Deiana, Maria G Alicicco, Chiara Ninniri, Anna N Santoro, Antonio Pazzola, Alessandro Fancellu
Publikováno v:
World journal of clinical oncology. 13(7)
Adjuvant chemotherapy is recommended in high-risk breast cancer. However, no universally accepted guidelines exist on pre-chemotherapy assessment. In particular, the number and frequency of medical visits vary according to each institution's policy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8aa552ca30a7d5bd709a4dcdea1b9a2c
https://pubmed.ncbi.nlm.nih.gov/36157162
https://pubmed.ncbi.nlm.nih.gov/36157162
Autor:
Giovanni M. Fadda, Renato Lobrano, Milena Casula, Marina Pisano, Antonio Pazzola, Antonio Cossu, Giuseppe Palmieri, Panagiotis Paliogiannis
Publikováno v:
Journal of Personalized Medicine. 12:1874
Lung cancer is one of the most common and lethal cancers worldwide. Numerous medications targeting specific molecular alterations in non-small cell lung cancer have been introduced in the last decade and have revolutionized the clinical management of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0c6f091f2e398de486dd54531ec8b83
https://doi.org/10.3390/jpm12111874
https://doi.org/10.3390/jpm12111874
Autor:
Matteo Lambertini, Daniele Generali, Antonio Frassoldati, Stefania Russo, Francesco Schettini, Antonio Pazzola, P. De Placido, Francesco Cognetti, Pierfranco Conte, Daniela Cianniello, Mariavittoria Locci, Mario Giuliano, A. Fabi, Filippo Montemurro, Sara Parola, Benedetta Conte, Valentina Guarneri, Fabio Puglisi, L. Del Mastro, M. De Laurentiis, Gaia Griguolo, S. De Placido, F. Riccardi, Grazia Arpino, Marta Bonotto, Giacomo Pelizzari, Claudia Bighin, Giuseppe Buono
Publikováno v:
ESMO Open
Background The current standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive (+) metastatic breast cancer is the combination of pertuzumab, trastuzumab and a taxane (P + T + taxane), while standard second-line is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6ee588c67442c4a520fdbc545ba61f6
http://hdl.handle.net/11588/879441
http://hdl.handle.net/11588/879441
Autor:
Giuseppina Sarobba, Francesca Caputo, Francesca Diodati, Caterina Caminiti, Rodolfo Mattioli, Antonio Russo, Mario Airoldi, Filippo Zerilli, Antonio Pazzola, Maria Antonietta Annunziata, Paolo Giordani, Elisa Iezzi, Claudio Verusio, Marcello Aragona, Giuseppe Maglietta, Silvia Novello, Stefania Gori, Rodolfo Passalacqua, Saverio Cinieri, Giuseppe Procopio, Carmine Pinto
Publikováno v:
JAMA Network Open
Key Points Question Does an implementation strategy integrating psychosocial care into cancer centers improve at least 1 of 2 domains (emotional or social function) of health-related quality of life? Findings This stepped-wedge cluster randomized cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ad5c1c63ab142ffeb59e84e9ee6d86e
http://hdl.handle.net/2318/1874422
http://hdl.handle.net/2318/1874422
Autor:
Giacomo Cartenì, Filippo de Marinis, Flavia Longo, Gianpiero Fasola, Domenico Galetta, Alberto Caprioli, Dario Giuffrida, Alberto Zaniboni, Valentina Acciai, Oscar Alabiso, Maria Rita Migliorino, Antonio Santo, Antonio Pazzola, Diego Cortinovis, Giampiero Romano, Sabrina Vari
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 143:783-791
Non-small cell lung cancer (NSCLC) is a condition with significant clinical burden for patients and relevant economic impact. Limited evidence exists on the management costs of NSCLC patients, especially in the late phases of the disease. The main ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0586e68c706596385fbea035d482ecb8
https://doi.org/10.1007/s00432-016-2326-x
https://doi.org/10.1007/s00432-016-2326-x